BioSpace News Archive

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced additional results from the pivotal Phase 3 MAESTRO-NASH biopsy clinical trial of resmetirom, a liver-directed selective thyroid hormone receptor agonist.

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), announced today that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for berdazimer gel, 10.3% (SB206) for the topical treatment of molluscum contagiosum (“molluscum”).

Icosavax, Inc. today provided a corporate update and highlighted anticipated milestones for 2023.

HTG Molecular Diagnostics, Inc. announced certain preliminary, unaudited financial results for the year ended December 31, 2022.

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced the establishment of its direct sales organization in Germany.

KBP Biosciences PTE. Ltd. today announced that an overview of Ocedurenone (KBP-5074) as a potential new treatment option addressing the unmet medical need of patients with uncontrolled and resistant hypertension and advanced CKD was presented by Pablo Pergola MD, PhD.

Corium LLC (Corium) announced that President and Chief Executive Officer, Perry J. Sternberg will present at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 4:00 p.m. Pacific.

Parnell Pharmaceuticals Holdings Ltd announced the extension of the backstopped rights offering to raise gross proceeds of approximately US$4.0 million.

Regulatory News: Transgene announces it has received clinical trial application approval from the French National Agency for the Safety of Medicines and Health Products to proceed with a Phase I clinical trial of TG6050, a novel oncolytic virus that will be administered intravenously in patients with advanced non-small cell lung cancer.

VISEN Pharmaceuticals announced that it has completed the double-blind period of PaTHway China Trial, a phase 3 China clinical trial for its innovative investigational new prodrug palopegteriparatide on January 4, 2023, and it would start to carry out analysis of the primary endpoints.